Targeting IL-13 as a Host-Directed Therapy Against Ulcerative Colitis

20Citations
Citations of this article
57Readers
Mendeley users who have this article in their library.

Abstract

The role of interleukin-13 in mediating ulcerative colitis remains under scrutiny. Compelling evidence from both man and mouse suggests that IL-13 not only contributes to the pathology associated with disease but is also involved in mediating the inflammatory response. These studies have led to the approach of targeting IL-13 as a promising treatment strategy in alleviating ulcerative colitis disease. Despite this evidence, recent clinical trial data suggests that specifically blocking the receptor through which IL-13 signals, IL-4 receptor-alpha (IL-4Rα) in ulcerative colitis patients, is insufficient in protecting them from disease outcome. This challenges the importance of IL-13 as a therapeutic target. This review describes the role of IL-13 in ulcerative colitis and current treatment strategies that target IL-13. The potential role of IL-13 signaling independently of IL-4Rα in mediating ulcerative colitis is highlighted as an important consideration when targeting the signaling mechanisms of IL-13 for therapeutic approaches.

Cite

CITATION STYLE

APA

Hoving, J. C. (2018, November 6). Targeting IL-13 as a Host-Directed Therapy Against Ulcerative Colitis. Frontiers in Cellular and Infection Microbiology. Frontiers Media S.A. https://doi.org/10.3389/fcimb.2018.00395

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free